To the Editor.
—In the article by Hand et al,1 significantly improved survival rates were shown in patients with stage III ovarian cancer who received platinum-based chemotherapy as compared with those who did not. In order to provide further population-based evidence on the favorable impact of platinumcontaining drugs, we took advantage of data on incident cases of ovarian cancer in the Registry of the Swiss Canton of Vaud (1980 population of about 530000). A more detailed description of the pathological characteristics and prognostic factors of these patients is provided elsewhere.2 Since information on treatment was absent, for the present comparison purposes, two calendar periods were chosen (1974 through 1981 and 1982 through 1988) on the basis of the time when platinum-containing drugs spread in Switzerland (J. de Vasconcellos, MD, Institute for Medical Information and Statistics, Zing, Switzerland, written communication, September 1992).A total of 649 new ovarian primary
Franceschi S, Levi F, La Vecchia C. Survival After Ovarian Cancer Treatment. JAMA. 1993;270(10):1196-1197. doi:10.1001/jama.1993.03510100046020